Remote Monitoring & Telemedicine for Leukemia Care

Overseen By Eleanor Rawlinson

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Colorado, Denver

Disqualifiers: Unstable condition, No caregiver, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 90 days

11 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial is testing a new way to help cancer patients manage their care at home using technology. It focuses on patients who have had bone marrow transplants or CAR-T therapy. The technology allows doctors to monitor patients' health remotely and provide quick medical advice and treatment when needed.

Research Team

Glen Peterson

Principal Investigator

University of Colorado, Denver

Eligibility Criteria

This trial is for adults aged 18-89 with leukemia who are stable enough to be discharged home after a bone marrow transplant or CAR-T therapy. They must have caregiver support, reliable phone and internet service, live within 45 minutes of the AMC in Denver, and agree to use technology for remote care.

Inclusion Criteria

I have someone to take care of me at home all the time.

My doctor says I am stable enough to go home for outpatient care.

Has self-reported reliable telephone and home internet service and a stable wireless network

Exclusion Criteria

Patients will be excluded from study participation if the PI or designated care provider believes study participation would not be in the patient's best interest for clinical reasons

Patients may also be excluded from study participation if in the opinion of the PI they have a medical condition that may impede their ability to adhere to the study protocol

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive technology-assisted in-home oncology care, including remote patient monitoring, telemedicine, and home-based health care services

90 days

Remote monitoring and telemedicine visits

Follow-up

Participants are monitored for safety and effectiveness after treatment, focusing on symptoms like febrile neutropenia, infection, cytokine release syndrome, and neurotoxicity

90 days

Treatment Details

Interventions

• BioIntelliSense BioButton Rechargable
• Memora Health two-way patient engagement platform provided by RC
• Technology-assisted in-home oncology care program

Trial Overview The study tests an at-home oncology care program using BioIntelliSense BioButton and Memora Health platform for patients post-BMT or CAR-T. It includes remote monitoring, telemedicine, and home health services to improve care coordination.

Participant Groups

Group I: Post BMT or CAR-T patients receiving care at UCHealth Experimental Treatment 2 Interventions

Participants will be recruited for this study from among three discrete patient populations: * Allogeneic BMT patients receiving care at UCHealth who are planning to reside in the Denver metro area within 45 minutes of the Anschutz Medical Campus (AMC) for at least 90 days post-transplant. * Autologous BMT patients receiving care at UCHealth who are planning to reside in the Denver metro Area within 45 minutes of the AMC for at least 30 days post-transplant. * CAR-T patients receiving care at UCHealth who are planning to reside in the Denver metro area within 45 minutes of the AMC for at least 30 days post treatment.

Who Is Running the Clinical Trial?

University of Colorado, Denver

Lead Sponsor

Trials

1,842

Recruited

3,028,000+

Reimagine Care

Collaborator

Trials

2

Recruited

20+